All articles by Abigail Beaney

Abigail Beaney

Abigail Beaney is the editor of Clinical Trials Arena. Abigail has expertise in clinical trial regulation, trial design, outsourcing, and cell and gene therapies. Abigail also has covered news and has a wealth of knowledge across several therapy areas including neurodegenerative, infectious and metabolic diseases. Abigail holds a first-class BA (Hons) degree in Journalism from the University of Central Lancashire in the United Kingdom. She has also obtained the National Qualification in Journalism through the UK's media industry body, the National Council for the Training of Journalists. Contact Abigail

AtaiBeckley’s MDMA-based drug for anxiety shows benefit in Phase IIa trial

AtaiBeckley’s social anxiety disorder (SAD) drug has shown both safety and early signs of efficacy in a Phase IIa trial.…
Podcast: Rare Disease Day: FDA guidance allowing advancement

It’s been a busy year for rare disease developers, with the US Food and Drug Administration (FDA) releasing several new…
Rare disease developers applaud clarity in FDA guidance

Stakeholders in the rare disease development community say that new guidance documents, released by the US Food and Drug Administration…
ViiV’s four-monthly HIV drug maintains viral suppression at 12 months

ViiV Healthcare’s investigational four-monthly HIV drug maintains viral suppression at 12 months in a Phase IIb trial. In the EMBRACE…
EU clinical trial target could bring in additional €4bn funding

A further €4bn ($4.72bn) a year in funding could come into Europe if targets to increase clinical trials in the…

Novo Nordisk-partnered drug shows 19.7% weight loss in Phase II trial

Novo Nordisk and United Laboratories’ jointly developed triple G drug has achieved a 19.7% weight loss in a Phase II…
HIV patients show lower steatotic liver disease with ViiV’s Dovato vs Biktarvy

Patients with HIV showed lower cases of steatotic liver disease when switched to ViiV Healthcare’s Dovato compared to Biktarvy. In…
Novo Nordisk’s CagriSema bested by Lilly’s Zepbound in head-to-head trial

Novo Nordisk’s CagriSema has been outperformed by Eli Lilly’s Zepbound (tirzepatide) in a head-to-head obesity trial. The Phase III REDEFINE…
UK MHRA raises concerns about puberty blocker trial

An investigator-led trial that is investigating puberty blockers in children and young people has been paused following concerns raised by…
The Bayesian challenge: complexity that pays off

Bayesian statistical models could help address recruitment challenges, but experts agree that sponsors must first understand – and be prepared…